AI inside your regulated perimeter, traceable by design.

Pharma decisions are not document decisions. They are records with ALCOA+ obligations, electronic-signature posture under 21 CFR Part 11 and EU Annex 11, change-control traces against filed dossiers, deviation histories that a quality review may reconstruct years later, and pharmacovigilance signals whose source data and decision trace must remain reconstructible inside the sponsor's perimeter.

Most AI platforms were built for a different customer — one that accepts vendor-hosted models, data paths a QP would never sign off on, and outputs whose provenance dissolves the moment the model is silently updated. A summary without a citation is not an answer a quality director can use. An output that cannot be reconstructed six months later is not an output a regulatory affairs director can defend.

deeplinq keeps the entire chain under institutional control. The orchestration layer, the connectors, the agents, the model router, the prompt archive, the retrieval index, and the decision trace all sit inside the environment the institution already defends. Data integrity stays operative as a platform concern, not a logging afterthought. The sections below open four workflows, the evidence layer they share, and the deployment envelope that holds them. deeplinq does not adjudicate quality decisions, does not sign batch releases, does not own pharmacovigilance signal closure. It produces and archives the data infrastructure those decisions depend on.

Your quality archive is the institutional memory of every deviation, CAPA, batch release, and supplier qualification — spread across QMS, EDMS, paper archives, and legacy quality software each site configured differently. The answers are in there ; no one is ever sure the archive is complete.

The platform queries this archive in plain language. Ask for every CAPA on product X with supplier-attributable root cause, deviations on line 3 correlating with the Q3 raw material change, batch records referencing the cleaning protocol revised last spring — and receive answers cited back to source records the QP can challenge and the auditor can trace.

Archive completeness surfaces as a query pattern : missing CAPA-closure signatures, qualifications outdated against current scope, investigations attached to deviations only on paper. Agents retrieve and cross-reference ; quality and QA decide which gaps to close, in what order, and on what timing.

ALCOA+ is a platform concern, not a post-hoc reconstruction. Every retrieval is attributed, every output cites its source, every interaction is archived with the model version that produced it. Boundary details are consolidated on /scope/.

Filed dossiers, authority correspondence, variation histories, commitments made in section X of an application that reach years later into a renewal or post-approval question. Reconstructing that record under an authority question means opening four systems against a clock the authority sets.

The platform queries the regulatory organization's own filed dossiers, correspondence, and change-control archive. Before : the regulatory affairs analyst opens four systems against the authority's clock. After : ask for the rationale supporting the limit in section 3.2.P.5.6 of a filed application and receive a sourced answer with model version and retrieval context pinned.

Cross-section consistency surfaces as a query pattern : commitments with thin operational record, variations not propagated downstream, authority follow-ups with incomplete responses. Regulatory affairs decides what to act on, drafts, reviews, submits.

Every workflow sits inside the sponsor organization. Boundary details on /scope/.

Adverse-event narratives. Signal-detection outputs. Periodic benefit-risk evaluations. Literature surveillance. Pharmacovigilance carries a standing load of case triage, signal review, and reporting deadlines under residency and jurisdictional constraints no vendor-hosted AI was designed to respect.

The platform queries the safety database the pharmacovigilance function already operates. Before : the safety officer reconstructs PSUR rationales from spreadsheets and case-by-case lookup. After : plain-language queries — 'show cases coded under PT X for product Y in the last reporting period', 'literature references since the last PSUR mentioning the signal flagged on product Z' — return cited answers.

Model-version pinning holds across reporting periods, so the rationale documented in one PSUR cycle reconstructs in the next. Every interaction archives prompt, retrieval, and decision trace.

Every retrieval stays inside your control zone. Boundary details on /scope/.

Quality agreements. CDMO batch-review documentation. Change notifications from API suppliers. Audit reports. Deviation notifications from CDMO partners. Supplier surveillance generates a standing flow of files quality reviews against contractual and regulatory expectations across dozens of external parties.

The platform queries the supplier archive the quality organization already holds. Before : the supply-quality reviewer chases CDMO closures across email, audit folders, and quality-agreement clauses. After : plain-language queries return cited answers — CDMO deviation closure status, outstanding API change notifications, audit findings cross-referenced against deviation trends.

Change-control continuity surfaces as a query pattern : qualifications renewed against shifted scope, deviation trends following sponsor process changes, audit findings whose verification record is missing. Quality prioritises and closes.

The platform reads supplier and CDMO data your organization already holds — no integration asked of suppliers. Boundary details on /scope/.

A regulatory inspection is not passed on claims. It is passed on evidence. deeplinq treats the evidence layer as a first-class platform concern, and narrows the evidence the platform produces from any model-assisted retrieval in a pharma context.

Every prompt and response is archived with full context. Every retrieval — document, record, field, correspondence — is attributed to its source. Every model call is logged with identifier, version pin, parameters, timestamp, outcome. Every agent action carries the decision trace: inputs, retrieved context, human approval status, access-control evaluation.

Model-version pinning is the structural backbone. The model that produced an output six months ago reconstructs the reasoning today. Silent substitution is eliminated by architecture. Electronic-records posture under 21 CFR Part 11 and EU Annex 11 is addressed through archival, access control, and signature-state handling. ALCOA+ principles stay operative across the full surface.

When an inspector asks for an evidence bundle scoped to a specific deviation, submission question, or quality event, the institution exports a structured archive covering every element above. No reconstruction project. No vendor-side retrieval.

deeplinq does not certify GxP compliance — no platform can. Compliance is a property of your validated system, your quality organization, your QP, and your regulatory function. What deeplinq produces is the evidence trail your auditor expects to see, with the integrity posture your quality function expects to preserve.

Pharma residency is not one question. It is several that the data itself asks.

Clinical trial data: residency obligations shaped by the country of conduct. Pharmacovigilance safety data: jurisdictional handling constraints per reporting territory, with the safety data and decision trace required to remain inside the rules of each authority's jurisdiction. Supplier and CDMO process data: contractual residency clauses your procurement and legal functions negotiated. Manufacturing batch records: QP access requirements under the institution's own control, not through a vendor tenancy.

Locking a pharma platform to a single model provider is a compliance decision, whether or not the institution frames it that way. The provider's roadmap becomes the institution's model roadmap. The provider's regulatory posture becomes a variable in the institution's inspection readiness. The provider's silent model updates become silent shifts in how a filed application is supported a year after submission.

deeplinq holds model choice behind an interface the institution controls. Cloud APIs for non-sensitive workloads where data residency can be enforced through vendor contracts. Open-weights models for on-premise or air-gapped deployments where the model lives inside the institutional perimeter. Selected by task, by data class, and by the institution's compliance posture for the workflow at hand. Model versions are pinned so an output produced during submission preparation can be reconstructed exactly during a post-approval authority question. Models can be replaced without rewriting the platform above them.

The pharma sub-section above is detailed first because operational archive depth — quality, regulatory affairs, pharmacovigilance, supplier archive intelligence — is where the evidence-and-residency posture is most concretely tested. Broader Healthcare workflows share that posture. The compliance frameworks change; the architecture does not.

Three workflow families to follow. Clinical operations and EHR-grounded knowledge work, where Hospital CIOs and Privacy Officers carry HIPAA Privacy and Security Rules, HITECH breach notification, and special-category personal data obligations. Medical devices and post-market surveillance, where 21 CFR Part 820, MDR Annex III, IVDR, ISO 13485 and ISO 14971 frame what regulatory affairs must reconstruct. Life sciences research and internal R&D knowledge, where the GxP context already established above continues to apply.

The Evidence Layer detailed in the pharma sub-section — model-version pinning, prompt and retrieval archival, decision traces, access-control evaluation — applies identically to broader Healthcare workflows. The four deployment modes detailed in the Deployment section above — on-premise, sovereign or private cloud, air-gapped, hybrid with a sovereignty boundary — apply identically. The boundary is the institution's environment. The architecture does not change with the workflow.